CA-GLOBALLOGIC
8.4.2024 14:38:30 CEST | Business Wire | Press release
GlobalLogic, a Hitachi group company, today announced a first-of-its-kind Platform-of-Platforms architecture designed to support deployment of enterprise-grade artificial intelligence (AI). GlobalLogic has designed the architecture to address the critical challenges every enterprise must overcome when operationalizing AI and generative AI (GenAI) at scale.
To realize the potential that AI promises, enterprises must address data privacy and security requirements, prevent intellectual property (IP) leakage and manage legal risks. They also need to identify an approach that allows for technical agility as new models, platforms and other innovations take shape. At the same time, leaders must manage organizational change and find effective strategies for controlling costs and driving return on AI/GenAI investments.
With over a decade of experience in delivering and deploying AI in software products and enterprise platforms, GlobalLogic offers a unique perspective on the design, data and engineering challenges of enterprise-grade, production-ready AI and GenAI. Created in partnership with leading hyperscalers and leveraging their foundational GenAI capabilities, GlobalLogic’s architecture is the first of its kind for unifying and industrializing enterprise-grade AI and GenAI solutions.
GlobalLogic identifies responsibility, reliability and reusability as key to enterprise-grade AI
“As companies work to move from AI and GenAI prototypes to enterprise-scale deployments, it has become clear that using this technology requires far more than sending prompts to a large language model (LLM),” said Sumit Sood, COO and Head of Engineering, GlobalLogic. “We have been helping enterprises adopt GenAI since 2021 and ‘traditional’ AI for much longer, often in life-critical situations. We understand what needs to be done to ensure responsibility, reliability and reusability in AI platforms.”
Sood explains that the responsibility tenet focuses on the goal of offering responses that are accurate, lawful and in compliance with security and governance requirements. The reliability tenet requires mechanisms for correcting model drift, hallucinations and security threats over time. Finally, the reusability tenet is crucial to implementing common data ingestion, preparation and model training and shared consumption mechanisms – which help contain costs and mitigate risk by preventing duplicative work.
GlobalLogic’s AI Platform-of-Platforms architecture addresses critical needs related to observability, security, governance and consumption. It makes it possible to integrate best-of-breed models, algorithms and solutions whether deployed in the cloud or on premises. It also includes accelerators for rapidly deploying some of the most sought-after use cases, including customer support and operations, software development and legacy migration, and enterprise knowledge management.
“The GenAI landscape is highly dynamic,” Sood said. “In an environment where the ‘best’ technology can change month to month or even week to week, GlobalLogic’s Platform-of-Platforms approach lets our clients pick the winners to deliver the best enterprise-class GenAI to support their business outcomes.”
To learn more about GlobalLogic’s AI solutions and advisory capabilities, visit www.globallogic.com/services/offerings/generative-ai/.
ABOUT GLOBALLOGIC
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408417447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
